Clinical data | |
---|---|
Trade names | Glucagen, Baqsimi, Gvoke, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682480 |
License data | |
Pregnancy category |
|
Routes of administration | Nasal, intravenous (IV), intramuscular injection (IM), subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C153H225N43O49S |
Molar mass | 3482.80 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Glucagon, sold under the brand name Baqsimi among others, is a medication and hormone.[9] As a medication it is used to treat low blood sugar, beta blocker overdose, calcium channel blocker overdose, and those with anaphylaxis who do not improve with epinephrine.[10] It is given by injection into a vein, muscle, or under the skin.[10] A version given in the nose is also available.[11]
Common side effects include vomiting.[10] Other side effects include low blood potassium and low blood pressure.[9] It is not recommended in people who have a pheochromocytoma or insulinoma.[10] Use in pregnancy has not been found to be harmful to the baby.[12] Glucagon is in the glycogenolytic family of medications.[10] It works by causing the liver to break down glycogen into glucose.[10]
Glucagon was approved for medical use in the United States in 1960.[10] It is on the World Health Organization's List of Essential Medicines.[13] It is a manufactured form of the glucagon hormone.[10] A generic version became available in the United States in December 2020.[14]
Ogluo EPAR
was invoked but never defined (see the help page).FDA PR 20190724
was invoked but never defined (see the help page).